Amgen is trading up 3.25% at $438.77 on October 20 after positive full Phase 3 CROSSING results for Tezspire in eosinophilic esophagitis. - The trial met co-primary and key secondary endpoints. Histologic remission at week 24 was 68.9% on 420 mg versus 3.5% on placebo; benefits continued through week 52. - Reuters reported the announcement; Amgen and AstraZeneca published results. Biotech rose 2.10%, but trial news was the clearer catalyst. No reliable volume figure was provided.